Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve test may predict lymphedema therapy success

NCT ID NCT07585253

Knowledge-focused Sponsor: Gaziler Physical Medicine and Rehabilitation Education and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether nerve signals (called sympathetic skin response) are linked to how well women respond to standard lymphedema therapy after breast cancer surgery. Thirty women with lymphedema and thirty healthy women had nerve tests and filled out symptom questionnaires. The lymphedema group then received three weeks of decongestive therapy, and researchers measured changes in arm swelling and quality of life. The goal was to understand the role of the autonomic nervous system in lymphedema treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jan 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of female patients aged 18-65 years with unilateral postmastectomy upper extremity lymphedema following breast cancer treatment and age-matched healthy female volunteers. Patients had completed breast cancer treatment protocols and had ISL stage I-II lymphedema. Healthy controls had no history of breast cancer, lymphedema, neurological disease, metabolic disorder, or systemic condition affecting autonomic nervous system function.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Healthy Control Inclusion Criteria: * Female volunteers aged between 18 and 65 years * No history of breast cancer or lymphedema * No neurological, metabolic, or systemic disease affecting autonomic nervous system function Healthy Control Exclusion Criteria: * History of breast cancer or lymphedema * Polyneuropathy * Diabetes mellitus * Hypothyroidism * Neurological disease * Systemic diseases affecting autonomic nervous system function Patient group; Inclusion Criteria: Inclusion Criteria: * Female patients aged between 18 and 65 years * Postmastectomy upper extremity lymphedema after breast cancer surgery * Completion of breast cancer treatment protocols * International Society of Lymphology (ISL) stage I-II lymphedema Exclusion Criteria: * Metastatic breast cancer * Bilateral breast cancer history * Bilateral upper extremity lymphedema * Ongoing chemotherapy or radiotherapy * Infection or allergic skin lesions on the upper extremities * Medical conditions causing edema, including decompensated heart, lung, or renal failure * Peripheral nervous system disease or polyneuropathy * Chronic endocrine, metabolic, neurological, or systemic diseases affecting autonomic nervous system function, including diabetes mellitus, hypo/hyperthyroidism, uremia, heart failure, cardiac arrhythmia, and uncontrolled hypertension * Presence of a cardiac pacemaker * Inability to tolerate electrical stimulation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autonomic dysfunction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Breast Cancer Lymphedema breast neoplasm lymphedema primary dysautonomia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autonomic dysfunction Breast cancer-related lymphedema Postmastectomy lymphedema

Contacts and locations

Locations

  • Gaziler Physical Medicine and Rehabilitation Training and Research Hospital

    Ankara, Ankara, 06800, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.